- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
Patent holdings for IPC class C07K 16/24
Total number of patents in this class: 7244
10-year publication summary
|
507
|
529
|
605
|
646
|
681
|
613
|
576
|
556
|
538
|
339
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Janssen Biotech, Inc. | 1764 |
241 |
| Novartis AG | 10262 |
223 |
| Abbvie Inc. | 1836 |
132 |
| Amgen Inc. | 4427 |
128 |
| Eli Lilly and Company | 4101 |
120 |
| Regeneron Pharmaceuticals, Inc. | 4701 |
115 |
| Genentech, Inc. | 4104 |
114 |
| MedImmune Limited | 610 |
98 |
| Sanofi | 4301 |
92 |
| Immatics Biotechnologies GmbH | 1127 |
76 |
| Hoffmann-La Roche Inc. | 3793 |
73 |
| Ablynx N.V. | 426 |
69 |
| F. Hoffmann-La Roche AG | 7837 |
65 |
| Chugai Seiyaku Kabushiki Kaisha | 1423 |
64 |
| Boehringer Ingelheim International GmbH | 4493 |
62 |
| The Regents of the University of California | 20745 |
54 |
| National University of Singapore | 2583 |
51 |
| Cedars-Sinai Medical Center | 1203 |
48 |
| Singapore Health Services Pte Ltd | 491 |
48 |
| UCB Biopharma SRL | 599 |
48 |
| Other owners | 5323 |